ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Pooled it
- Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.Cancers · 2026Review
- Recurrence Patterns and Management after Pleurectomy Decortication for Pleural Mesothelioma.Annals of surgery · 2026Article
- The Role of Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: State of the Art.Journal of personalized medicine · 2025Review
- Radiotherapy of the pleural cavity in patients with primary and secondary malignancies of the pleura.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesothelioma.JTCVS open · 2023Article
- Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors.Thoracic cancer · 2023Article
- Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma.Translational lung cancer research · 2023Article
- Contemporary issues in the surgical management of pleural mesothelioma.Journal of surgical oncology · 2023Review
- Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.Frontiers in endocrinology · 2023Article
- Malignant Pleural Mesothelioma: Current Understanding of the Immune Microenvironment and Treatments of a Rare Disease.Cancers · 2022Review
- Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities.Journal of radiation research · 2022Article
- [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper].Pneumologie (Stuttgart, Germany) · 2021Review
- GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma.World journal of clinical oncology · 2021Review
- CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.Lung cancer (Amsterdam, Netherlands) · 2021Review
- GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.World journal of clinical oncology · 2021Review
- Does size matter? -a population-based analysis of malignant pleural mesothelioma.Translational lung cancer research · 2020Article
- Commentary: Return to intended radiation therapy-Criteria for resection?The Journal of thoracic and cardiovascular surgery · 2019Article
- Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.European radiology · 2019Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
introductionHigher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D).
methodsWe analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan-Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure-free survival and progression-free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors.
resultsThe median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%).
conclusionsTrimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.